IOVA — Iovance Biotherapeutics Share Price
0.000.00%
Last trade - 00:00- $1.07bn
- $748.65m
- $164.07m
- 31
- 23
- 29
- 17
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.51 | ||
| Price to Tang. Book | 2.5 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.53 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -50.16% | ||
| Return on Equity | -57.48% | ||
| Operating Margin | -240.92% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 1.19 | 164.07 | 453.93 | 735.83 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.
Directors
- Iain Dukes CHM (62)
- Frederick Vogt PRE (48)
- Jean-marc Bellemin CFO (48)
- Igor Bilinsky COO (48)
- Michael Swartzburg VFN (53)
- Friedrich Graf Finckenstein OTH (54)
- Athena Countouriotis DRC (49)
- Ryan Maynard IND (51)
- Merrill Mcpeak IND (85)
- Wayne Rothbaum IND (53)
- Michael Weiser IND (58)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 1st, 2017
- Public Since
- June 20th, 2008
- No. of Shareholders
- 18
- No. of Employees
- 838
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 305,252,194
- Address
- 825 INDUSTRIAL ROAD, 4TH FLOOR, SAN CARLOS, 94070
- Web
- https://www.iovance.com/
- Phone
- +1 6502607120
- Auditors
- Ernst & Young LLP
Upcoming Events for IOVA
Iovance Biotherapeutics Inc Corporate Call
Iovance Biotherapeutics Inc Annual Shareholders Meeting
Q2 2025 Iovance Biotherapeutics Inc Earnings Release
Similar to IOVA
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Iovance Biotherapeutics share price?
As of Today at 21:23 UTC, shares in Iovance Biotherapeutics are trading at $3.51. This share price information is delayed by 15 minutes.
How has the Iovance Biotherapeutics share price performed this year?
Shares in Iovance Biotherapeutics last closed at $3.51 and the price had moved by -69.58% over the past 365 days. In terms of relative price strength the Iovance Biotherapeutics share price has underperformed the S&P500 Index by -71.93% over the past year.
What are the analyst and broker recommendations for Iovance Biotherapeutics?
The overall consensus recommendation for Iovance Biotherapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Iovance Biotherapeutics dividend yield?
Iovance Biotherapeutics does not currently pay a dividend.
Does Iovance Biotherapeutics pay a dividend?
Iovance Biotherapeutics does not currently pay a dividend.
When does Iovance Biotherapeutics next pay dividends?
Iovance Biotherapeutics does not currently pay a dividend.
How do I buy Iovance Biotherapeutics shares?
To buy shares in Iovance Biotherapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Iovance Biotherapeutics?
As of the previous close price of $3.51, shares in Iovance Biotherapeutics had a market capitalisation of $1.07bn.
Where are Iovance Biotherapeutics shares listed?
Here are the trading details for Iovance Biotherapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: IOVA
What kind of share is Iovance Biotherapeutics?
Based on an overall assessment of its quality, value and momentum Iovance Biotherapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Iovance Biotherapeutics share price forecast for 2025?
The analyst consensus target price for shares in Iovance Biotherapeutics is $19.18. That is 446.44% above the last closing price of $3.51.
Analysts covering Iovance Biotherapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.79 for the next financial year.
Find out moreWhat is the trend in the Iovance Biotherapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Iovance Biotherapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -65.33%.
As of the last closing price of $3.51, shares in Iovance Biotherapeutics were trading -53.86% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Iovance Biotherapeutics PE Ratio?
The Iovance Biotherapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.51.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Iovance Biotherapeutics?
Iovance Biotherapeutics' management team is headed by:
- Iain Dukes - CHM
- Frederick Vogt - PRE
- Jean-marc Bellemin - CFO
- Igor Bilinsky - COO
- Michael Swartzburg - VFN
- Friedrich Graf Finckenstein - OTH
- Athena Countouriotis - DRC
- Ryan Maynard - IND
- Merrill Mcpeak - IND
- Wayne Rothbaum - IND
- Michael Weiser - IND